María Santamaría-Cadavid1, Emilio Rodríguez-Castro1, Manuel Rodríguez-Yáñez1, Susana Arias-Rivas1, Iria López-Dequidt1, María Pérez-Mato1, Manuel Rodríguez-Pérez1, Ignacio López-Loureiro1, Pablo Hervella1, Francisco Campos1, José Castillo1, Ramón Iglesias-Rey2, Tomás Sobrino3. 1. Clinical Neurosciences Research Laboratory, Clinical University Hospital, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico, c/ Travesa da Choupana, s/n, 15706, Santiago de Compostela, Spain. 2. Clinical Neurosciences Research Laboratory, Clinical University Hospital, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico, c/ Travesa da Choupana, s/n, 15706, Santiago de Compostela, Spain. ramon.iglesias.rey@sergas.es. 3. Clinical Neurosciences Research Laboratory, Clinical University Hospital, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico, c/ Travesa da Choupana, s/n, 15706, Santiago de Compostela, Spain. tomas.sobrino.moreiras@sergas.es.
Abstract
BACKGROUND: Recent preclinical studies have shown that regulatory T cells (Treg) play a key role in the immune response after ischemic stroke (IS). However, the role of Treg in human acute IS has been poorly investigated. Our aim was to study the relationship between circulating Treg and outcome in human IS patients. METHODS: A total of 204 IS patients and 22 control subjects were recruited. The main study variable was good functional outcome at 3 months (modified Rankin scale ≤2) considering infarct volume, Early Neurological Deterioration (END) and risk of infections as secondary variables. The percentage of circulating Treg was measured at admission, 48, 72 h and at day 7 after stroke onset. RESULTS: Circulating Treg levels were higher in IS patients compared to control subjects. Treg at 48 h were independently associated with good functional outcome (OR, 3.5; CI: 1.9-7.8) after adjusting by confounding factors. Patients with lower Treg at 48 h showed higher frequency of END and risk of infections. In addition, a negative correlation was found between circulating Treg at 48 h (r = - 0.414) and 72 h (r = - 0.418) and infarct volume. CONCLUSIONS: These findings suggest that Treg may participate in the recovery of IS patients. Therefore, Treg may be considered a potential therapeutic target in acute ischemic stroke.
BACKGROUND: Recent preclinical studies have shown that regulatory T cells (Treg) play a key role in the immune response after ischemic stroke (IS). However, the role of Treg in human acute IS has been poorly investigated. Our aim was to study the relationship between circulating Treg and outcome in humanISpatients. METHODS: A total of 204 ISpatients and 22 control subjects were recruited. The main study variable was good functional outcome at 3 months (modified Rankin scale ≤2) considering infarct volume, Early Neurological Deterioration (END) and risk of infections as secondary variables. The percentage of circulating Treg was measured at admission, 48, 72 h and at day 7 after stroke onset. RESULTS: Circulating Treg levels were higher in ISpatients compared to control subjects. Treg at 48 h were independently associated with good functional outcome (OR, 3.5; CI: 1.9-7.8) after adjusting by confounding factors. Patients with lower Treg at 48 h showed higher frequency of END and risk of infections. In addition, a negative correlation was found between circulating Treg at 48 h (r = - 0.414) and 72 h (r = - 0.418) and infarct volume. CONCLUSIONS: These findings suggest that Treg may participate in the recovery of ISpatients. Therefore, Treg may be considered a potential therapeutic target in acute ischemic stroke.
Entities:
Keywords:
Early neurological deterioration; Interleukin-10; Ischemic stroke; Neuroinflammation; Regulatory T cells; Risk factors
Authors: Jonathan Howard DeLong; Sarah Naomi Ohashi; Kevin Charles O'Connor; Lauren Hachmann Sansing Journal: Semin Immunopathol Date: 2022-06-29 Impact factor: 11.759